Background: The placement of a cochlear implant (CI) can restore auditory function in the case of profound cochlear deafness, which may be due to Ménière's disease (MD) or be associated with symptoms related to endolymphatic hydrops. The usual treatment of disabling vertigo in MD is based on vestibular deafferentation by labyrinth ablation. The aim of the present study was to retrospectively evaluate the efficacy of the CI in the control of disabling vestibular manifestations in the case of MD unresponsive to medical treatments.
Methods: A case series of five MD patients with disabling vestibular manifestations associated with profound hearing loss was included. A complete audio-vestibular evaluation was performed after CI positioning.
Results: All patients reported clinical benefits after implant positioning: no vestibular crisis was reported after the surgery. The vHIT and the caloric test showed a normal function or a mild vestibular hypofunction. The auditory performances were comparable to those in the general implanted population. All patients reported subjective tinnitus reduction.
Conclusions: To date, very few studies have reported vestibular outcomes in hydropic pathology on the implanted side; our results are encouraging. We can therefore confirm the efficacy and safety of the CI as a unique treatment for hearing loss, dizziness, and tinnitus in case of disabling cochlear hydrops, especially in those patients where the history of the disease requires preservation of the vestibular function.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331512 | PMC |
http://dx.doi.org/10.3390/audiolres12040040 | DOI Listing |
Cardiovasc Revasc Med
December 2024
Division of Cardiovascular Medicine, University of Toledo Medical Center, Toledo, OH, United States of America. Electronic address:
Background: Percutaneous left atrial appendage occlusion (pLAAO) presents an alternative to anticoagulation (AC) for stroke prophylaxis in atrial fibrillation (Afib) patients with high bleeding risk. pLAAO was associated with lower rates of disabling stroke which was mainly attributed to the reduction of hemorrhagic stroke (HS). Little is known about the impact of pLAAO on the severity of ischemic strokes which we sought to study.
View Article and Find Full Text PDFJ Affect Disord
December 2024
Suzhou Guangji Hospital, The Affiliated Guangji Hospital of Soochow University, Suzhou, China. Electronic address:
Background: Anxiety disorders are widespread across the world. Understanding the global burden of anxiety disorders in the past and future can provide important references for optimizing prevention and control strategies in healthcare systems.
Methods: The estimation of anxiety disorders in the Global Burden of Disease Study 2021 using systematic review was conducted to describe incidence, prevalence and disability adjusted life years (DALYs) in 204 countries and regions from 1990 to 2021.
Disabil Rehabil
December 2024
Margalla Institute of Health Sciences, Rawalpindi, Pakistan.
Purpose: To linguistically and cross-culturally translate Hip Disability and Osteoarthritis Outcome Score into Urdu language (HOOS-U), and test its psychometric properties among patients with hip pain.
Materials And Methods: Translation and cross-cultural adaptation of English version of HOOS were carried out following international guidelines. Psychometric testing included reliability (internal consistency and test-retest reliability), validity (content and construct validity) and responsiveness.
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
GUTA-CLINIC LLC, Moscow, Russia.
Objective: Evaluation of the safety and effectiveness of Relatox, botulinum toxin type A in patients with focal spasticity (FS) of the upper limb as a result of a cerebrovascular accident (CVA) or traumatic brain injury (TBI).
Material And Methods: A multicenter, prospective, single-blinded, randomized, comparative clinical study included 210 patients of both sexes aged 18-75 years after moderate to severe TBI and CVA in seven sites in the Russian Federation. The patients were randomized into two groups.
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
Smolensk State Medical University, Smolensk, Russia.
Objective: To study the quality of life (QoL) of patients with multiple sclerosis (MS) in the Smolensk region who receive MS disease-modifying therapies (DMT).
Material And Methods: The study included 37 patients receiving MS DMT. The 36-Item Short Form Health Survey (SF-36), the Multiple sclerosis Quality of Life (MusiQol), the Hamilton Depression Rating Scale, a scale of satisfaction with treatment, the Fatigue Severity Scale were administered.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!